NICE TA347: nintedanib for previously treated locally advanced, metastatic or locally recurrent non-small cell lung cancer. (Decision date - August 2015)
NICE TA379: nintedanib for treating idiopathic pulmonary fibrosis. (Decision date - February 2016)
NICE TA747 - Nintedanib for treating progressive fibrosing interstitial lung diseases. (Decision date - December 2021)
NICE TA864 - Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted (Decison date - March 2023)
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
